PharmaResources (Shanghai) (301230) Stock Overview
Operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
301230 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
PharmaResources (Shanghai) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥26.13 |
| 52 Week High | CN¥36.99 |
| 52 Week Low | CN¥24.00 |
| Beta | 0.84 |
| 1 Month Change | -8.41% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301230 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -23.9% | -5.5% | -4.7% |
| 1Y | n/a | 28.1% | 10.6% |
Return vs Industry: Insufficient data to determine how 301230 performed against the CN Life Sciences industry.
Return vs Market: Insufficient data to determine how 301230 performed against the CN Market.
Price Volatility
| 301230 volatility | |
|---|---|
| 301230 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 12.3% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 301230's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: Insufficient data to determine 301230's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,155 | Ping Chen | www.pharmaresources.cn |
PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturing organization (CDMO), and commercial manufacturing services for small molecule drugs. It is also involved in the research, development, and customized/commercial production of active pharmaceutical ingredients and key intermediates, including ticagrelor, oxiracetam, l-carnitine, velpatasvir, peramivir trihydrate, huperzine A, and vitamin K2, as well as design, screening, and optimization of hit compounds and lead compounds; conducting of structural improvements; and provision of preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights.
PharmaResources (Shanghai) Co., Ltd. Fundamentals Summary
| 301230 fundamental statistics | |
|---|---|
| Market cap | CN¥4.67b |
| Earnings (TTM) | CN¥46.10m |
| Revenue (TTM) | CN¥691.21m |
Is 301230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301230 income statement (TTM) | |
|---|---|
| Revenue | CN¥691.21m |
| Cost of Revenue | CN¥507.48m |
| Gross Profit | CN¥183.72m |
| Other Expenses | CN¥137.62m |
| Earnings | CN¥46.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 28, 2026
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 26.58% |
| Net Profit Margin | 6.67% |
| Debt/Equity Ratio | 1.0% |
How did 301230 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 17:34 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaResources (Shanghai) Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Wang | Citic Securities Co., Ltd. |
| Zhengyang Wang | Citic Securities Co., Ltd. |